CA3192456A1 - Single domain antibodies - Google Patents

Single domain antibodies

Info

Publication number
CA3192456A1
CA3192456A1 CA3192456A CA3192456A CA3192456A1 CA 3192456 A1 CA3192456 A1 CA 3192456A1 CA 3192456 A CA3192456 A CA 3192456A CA 3192456 A CA3192456 A CA 3192456A CA 3192456 A1 CA3192456 A1 CA 3192456A1
Authority
CA
Canada
Prior art keywords
seq
cdr3
single domain
cdr2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3192456A
Other languages
English (en)
French (fr)
Inventor
Jiandong HUO
Raymond Owens
James Naismith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosalind Franklin Institute
Original Assignee
Rosalind Franklin Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2014451.5A external-priority patent/GB202014451D0/en
Priority claimed from GBGB2014453.1A external-priority patent/GB202014453D0/en
Priority claimed from GBGB2108319.1A external-priority patent/GB202108319D0/en
Application filed by Rosalind Franklin Institute filed Critical Rosalind Franklin Institute
Publication of CA3192456A1 publication Critical patent/CA3192456A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3192456A 2020-09-14 2021-09-14 Single domain antibodies Pending CA3192456A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2014453.1 2020-09-14
GBGB2014451.5A GB202014451D0 (en) 2020-09-14 2020-09-14 Single domain antibodies
GB2014451.5 2020-09-14
GBGB2014453.1A GB202014453D0 (en) 2020-09-14 2020-09-14 Linker
GBGB2108319.1A GB202108319D0 (en) 2021-06-10 2021-06-10 Single domain antibodies
GB2108319.1 2021-06-10
PCT/GB2021/052383 WO2022053839A1 (en) 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2

Publications (1)

Publication Number Publication Date
CA3192456A1 true CA3192456A1 (en) 2022-03-17

Family

ID=77951755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3192456A Pending CA3192456A1 (en) 2020-09-14 2021-09-14 Single domain antibodies

Country Status (7)

Country Link
US (1) US20230374116A1 (https=)
EP (1) EP4211157A1 (https=)
JP (1) JP2023542107A (https=)
KR (1) KR20240102916A (https=)
AU (1) AU2021339978A1 (https=)
CA (1) CA3192456A1 (https=)
WO (1) WO2022053839A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
CN117603358B (zh) * 2023-02-24 2024-11-01 中国科学院微生物研究所 一种广谱新型冠状病毒的双特异性抗体
CN118255878A (zh) * 2024-04-15 2024-06-28 深圳细胞谷生物医药有限公司 SARS-CoV-2驼源纳米抗体或其抗原结合片段、及其组合物和应用
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법

Also Published As

Publication number Publication date
WO2022053839A1 (en) 2022-03-17
EP4211157A1 (en) 2023-07-19
US20230374116A1 (en) 2023-11-23
KR20240102916A (ko) 2024-07-03
JP2023542107A (ja) 2023-10-05
AU2021339978A9 (en) 2024-10-10
AU2021339978A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US20230374116A1 (en) Single domain antibodies that target sars-cov-2
AU2020286284B2 (en) Novel anti-CD39 antibodies
JP2020171288A (ja) インフルエンザヘマグルチニンに対する結合分子及びその使用
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
US20230331824A1 (en) Single-domain antibodies that bind sars-cov-2
JP6050747B2 (ja) インフルエンザ受動免疫化に有用な抗体
CN113583116A (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
US20240207401A1 (en) Coronavirus antibody
CA3215698A1 (en) Pan-specific corona virus binders
US20240270826A1 (en) Antibodies that bind sars-cov-2 spike protein
US20230357364A1 (en) Covid-19 antibodies and uses thereof
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
US20240228595A1 (en) Methods for Monoclonal Antibody Generation
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
WO2022068844A1 (en) Neutralizing antibody against sars-cov-2
EP4063384A1 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
CN117042799A (zh) 靶向sars-cov-2的单结构域抗体
CA3267635A1 (en) Antivirals against human parainfluenza virus
WO2024068744A1 (en) Antivirals against human parainfluenza virus
US20240262892A1 (en) Neutralizing antibodies against sars-cov-2
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260304